Services
Central Lab
Gene and Genome Center
Pathology and IHC Center
Hematologic and FCM Center
Biochemical Immune Center
Mass Spectrometry Center
Pathogen Microorganism Culture and Drug Sensitivity
Project Management
Bioanalysis
Collection Kits Management
Cold-chain Logistics Management
Specimen Management
Lab Data Management
Solutions
Solutions
Solid Tumors
Hematological Malignancies
Endocrine and Metabolic Diseases
Infectious Diseases
Vaccines
Inflammation and Immune Diseases
Neurological Diseases
Cell and Gene Therapy
Biomarkers
Companion Diagnostics
About
About
About KingMylab
Culture
Milestones
Quality Control
Our Team
Global Strategic Laboratory Alliance
News Center
Join Us
Human Resources
Join KingMylab
Benefit
Employee Activity
Contact
中文
EN
News Center
Back
2024年终回顾 | 金墁利医药助力12款新药及新适应症、生物类似药获NMPA批准上市
publish time：2024-12-31
Prev：
精彩回顾 | 驭势奋进 墁途共赢—临床研究创新发展与合作交流研讨会暨金墁利医药（上海）临床试验实验室落成开放日活动圆满落幕
Next：
喜报 | 金墁利医药助力正大天晴PD-L1「贝莫苏拜单抗」获批新适应症
×
Contact Us
Top
